TC
CSTL icon

Truvestments Capital’s Castle Biosciences CSTL Stock Holding History

Truvestments Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-135
Closed -$3.18K – 730
2022
Q4 		$3.18K Buy
+135
New +$3.13K ﹤0.01% 637

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Truvestments Capital's CSTL Position: Q1 2023 in Review

Truvestments Capital sold out of Castle Biosciences (CSTL) in Q1 2023, closing a stake of 135 shares — an estimated $3.18K sold.

Truvestments Capital first reported a position in CSTL in Q4 2022 and held it in 1 quarter. The position peaked at $3.18K in Q4 2022. 148 funds tracked by Wall St. Rank hold CSTL as of Q1 2023.

  • Truvestments Capital reported no remaining Castle Biosciences position as of Q1 2023 after selling out during the quarter.
  • Truvestments Capital sold 135 Castle Biosciences shares in Q1 2023, an estimated $3.18K.
  • Truvestments Capital first reported a position in Castle Biosciences in Q4 2022 and held it in 1 quarter.
  • Truvestments Capital's Castle Biosciences position peaked at $3.18K in Q4 2022.
  • 148 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2023.

Based on Truvestments Capital's 13F filing for Q1 2023, filed 12 May 2023.